CTRI/2021/08/035567尚未招募2 期
A Prospective, Randomized, open-labelled, active Comparator trial of Indomethacin and standard care versus Standard care among hospitalized severe Covid-19 patients.
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- IIT Madras
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age between 20 to 90 years
- •RT â?? PCR Positive
- •Hospitalised patients
- •A blood oxygen saturation of 93% or less
- •A ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Pao2:Fio2) of less than 300 mm Hg, or infiltrates in more than 50% of the lung field
排除标准
- •Hypersensitivity/Allergy to Drug
- •Recent Heart attack
- •Severe Asthma
- •Acute Kidney Injury
- •Patients with known history of Indomethacin allergy will be excluded from the study.
研究者
相似试验
招募中
2 期
Comparison of efficacy of Indomethacin vs Paracetamol along with standard care of treatment in mild and moderate Covid-19 patientsCTRI/2021/05/033544IIT Madras
招募中
3 期
A clinical study to assess efficacy and safety of Febuxostat ER Tablet versus Febuxostat IR TabletCTRI/2024/01/061844AKUMS DRUGS PHARMACEUTICALS LTD
进行中（未招募）
1 期
A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTSTreatment of proven or probable invasive aspergillosis (IA) and rare molds such asScedosporium or Fusarium species.MedDRA version: 9.1Level: LLTClassification code 10003488Term: AspergillosisMedDRA version: 9.1Level: LLTClassification code 10051919Term: Fusarium infectionMedDRA version: 9.1Level: LLTClassification code 10059045Term: Scedosporium infectionEUCTR2008-005275-10-HUPfizer Inc, 235 East 42nd Street, New York, NY 1001731
进行中（未招募）
不适用
A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTSEUCTR2008-005275-10-BGPfizer Inc, 235 East 42nd Street, New York, NY 1001736
进行中（未招募）
不适用
A prospective, Open-Label, Non-randomized, Multi-Center Study to Investigate the Safety and Tolerability of Voriconazole as Primary Therapy for Treatment of Invasive Aspergillosis and Molds such as Scedosporium or Fusarium Species in Pediatric PatientsTreatment of proven or probable invasive aspergillosis (IA) and rare molds such as Scedosporium or Fusarium species.MedDRA version: 14.1Level: PTClassification code 10003488Term: AspergillosisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10059045Term: Scedosporium infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10051919Term: Fusarium infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-005275-10-Outside-EU/EEAPfizer Inc, 235 East 42nd Street, New York, NY 1001736